The impermeability of the luminal endothelial cell monolayer is crucial for the normal performance of the vascular and lymphatic systems. A key to this function is the integrity of the monolayer's intercellular junctions. The known repertoire of junction-regulating genes is incomplete. Current permeability assays are incompatible with high-throughput genome-wide screens that could identify these genes. To overcome these limitations, we designed a new permeability assay that consists of cell monolayers grown on ~150 μm microcarriers (MCs). Each MC functions as a miniature individual assay of permeability (MAP). We demonstrate that false-positive results can be minimized, and that MAP sensitivity to thrombin-induced increase in monolayer permeability is similar to the sensitivity of impedance measurement. We validated the assay by showing that the expression of single guide RNAs (sgRNAs) that target genes encoding known thrombin signaling proteins blocks effectively thrombin-induced junction disassembly, and that MAPs carrying such cells can be separated effectively by fluorescence-assisted sorting from those that carry cells expressing non-targeting sgRNAs. These results indicate that MAPs are suitable for high-throughput experimentation and for genome-wide screens for genes that mediate the disruptive effect of thrombin on endothelial cell junctions.
Recommended CitationSimonneau, Claire; Yang, Junning; Kong, Xianguo; Kilker, Robert; Edelstein, Leonard; Fortina, Paolo; Londin, Eric R.; and Horowitz, Arie, "Validation of a Miniaturized Permeability Assay Compatible with CRISPR-Mediated Genome-Wide Screen." (2019). Cardeza Foundation for Hematologic Research. Paper 50.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.